FIVE at FIVE AU: Rio to unlock giant ore body; China delays GDP figures; rental crisis hits inflation
The Reserve Bank of Australia has said that Australia's rental crisis is contributing to high inflation.
Company
Radiopharm Theranostics Ltd
ASX:RAD
Radiopharm Theranostics is a clinical-stage biotech company revolutionizing cancer care through the development of first-in-class radiopharmaceuticals. The company is advancing a pipeline of distinct radiopharmaceutical technologies for novel oncology targets—avoiding "me-too" targets like Prostate-Specific Membrane Antigen (PSMA), Fibroblast Activation Protein (FAP) or Somatostatin Receptor 2 (SSTR2).
101 stories · page 3 of 6
Radiopharm Theranostics welcomes positive Phase 2 data for F-18 Pivalate in brain metastases trial
Radiopharm has an exclusive worldwide licence for the Pivalate platform technology from Cancer Research Technology Limited and Imperial College London.
Radiopharm Theranostics welcomes proof of concept for LRRC15 tumour targeting from prestigious scientific journal publication
The company says the publication of this evidence in Nature strengthens its already robust assessment of LRRC15 as a biomarker for aggressive malignancies, which it will follow up with a clinical trial assessing DUNP15's effect on the prote
Radiopharm Theranostics has Ga68-Integrin (RAD301) selected for presentation at European Association of Nuclear Medicine congress
“It is a pleasure to see the excellent work of the medical team from Dresden receive this recognition by the EANM committee for their first translation of TRIMT´s Trivehexin (RAD301) in the clinical setup,” said RAD CEO and MD Riccardo Cane
Radiopharm Theranostics to present interim data and continues to validate work with brain cancer
“We are very pleased to see a new molecule and an innovative mode of action in an area of high unmet medical need and we cannot wait to see the data presented,” Radiopharm’s CEO and managing director Riccardo Canevari.
Radiopharm Theranostics enters supply agreement to strengthen clinical pipeline of radiopharmaceutical products
“We are excited that our isotopes will play a critical role in Radiopharm Theranostics’ programs that aim to revolutionise cancer treatment,” SHINE’s Therapeutics Division general manager Chris Vessell said.
Radiopharm Theranostics shares surge after securing FDA's rare paediatric disease designation for DUNP19 technology
Radiopharm signed an exclusive licensing agreement with University of California Los Angeles (UCLA) for the promising LRRC15 antibody DUNP19 in April 2022.
Radiopharm Theranostics and MD Anderson launch joint venture to develop novel radiopharmaceuticals
The new entity formed by the medtech and the university will bring together product development expertise and clinical innovation.
Radiopharm Theranostics secures orphan drug designation for DUNP19 osteosarcoma treatment
“The resulting benefits of orphan designation will allow us to continue the development work of DUNP19’s inventor Dr David Ulmert with an even greater level of confidence," CEO and MD Riccardo Canevari said.
Radiopharm Theranostics’ key partnerships aiding progress in clinical trials: Diamond Equity Research
The NYC-based global equity research firm has valued Radiopharm at A$0.88 per share, an implied upside of more than four-fold from Radiopharm’s current share price of A$0.21
Radiopharm Theranostics inks Lantheus strategic collaboration; secures NM-01 licensing agreement with Nanomab
“We look forward to seeing the results of the Phase 2 PD-L1 imaging trial and to continuing our relationship with Lantheus into the future,” CEO and MD Riccardo Canevari said.
Radiopharm Theranostics extends agreement for Australian prostate cancer trial with GenesisCare
“GenesisCare is a leader in cancer care and to further the relationship with the company adds to our confidence as we move through the various steps in our clinical development,” CEO and MD Riccardo Canevari said.
Radiopharm Theranostics’ next-generation imaging data presented at Sixth World Theranostics Conference
The results concluded that Ga-68-Trivehexin is a promising non-invasive molecular imaging agent for certain head, neck and pancreatic tumours, with the potential to replace 18F-FDG as the standard-of-care radiotracer.
Radiopharm Theranostics strengthens Scientific Advisory Board with highly credentialed professor
“Susann [Brady-Kalnay] brings to the Scientific Advisory Board another excellent knowledge base and degree of experience in the molecular theranostic field," Radiopharm Theranostics managing director and CEO Riccardo Canevari said.
Radiopharm Theranostics signs new agreement to accelerate asset development
The agreement supplies RAD Lutetium-177 NCA, a key isotope required for multiple clinical trials in RAD's clinical pipeline, and thus the ability to accelerate several assets.
Radiopharm Theranostics secures brain tumour-targeting technology for clinical pipeline portfolio
“A number of tumour types can be detected with this novel PTPµ-targeted agent. Due to the limited treatment options and immediate need for therapies, we are focused on detecting and treating aggressive brain tumours with the PTPµ-targeted a
Radiopharm Theranostics appoints ex big pharma leader to board
Dr Leila Alland has a wealth of experience including leadership roles at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, where she contributed to multiple successful drug approvals.
Radiopharm Theranostics appoints highly experienced COO
“Having known Vittorio from our previous experiences in the sector and with AAA, I’m very confident in the expertise and capability he will bring to Radiopharm,” Radiopharm CEO and managing director Riccardo Canevari says.
Radiopharm Theranostics’ AVβ6-Integrin platform gains recognition in Europe as it continues clinical progress
AVβ6 offers noteworthy performance for radiolabelling and is a promising candidate for the early detection of challenging cancers such as pancreatic and head & neck cancer by PET imaging.
Radiopharm Theranostics’ transformative acquisition and progress in clinical trials to drive value: Diamond Equity Research
Diamond Equity Research updated its valuation for Radiopharm following the signing of an exclusive antibody licensing agreement with the University of California Los Angeles (UCLA).